30. A method for monitoring the circulating level of a selected agent characterized by the ability to induce a hematopoietic synergistic factor in a mammal comprising:

contacting a blood sample from the mammal with an antibody according to claim 28 [or 29],

measuring levels of circulating HSF, and

comparing said circulating HSF levels following administration of said agent to circulating HSF levels prior to administration of said agent.

REMARKS

The amendments presented above have been introduced to delete the allowed subject matter in U.S. Serial No. 08/557,142. No new matter has been added.

No new matter has been introduced.

Respectfully submitted,

Inda E Hael

Linda E. Hall

Attorney for Applicants Registration No. 31,763

SMITHKLINE BEECHAM CORPORATION Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-5016 Facsimile (610) 270-5090 N:\LEH\CASES\P5016\CPA\DI\PREAMEND.DOC

1.0 1.00 millionia man in the first mile of the first mile of the first man in the first ma